WebMay 12, 2024 · Crystal structure of human Cdk12/Cyclin K in complex with the inhibitor BSJ-01-175. Released: 12 May 2024. DOI: 10.2210/pdb7nxk/pdb. Source organism: Homo … WebBSJ-01-175. CAT NO. : 2227392-55-2. CAS NO. : 2227392-55-2. Inquiry. Quick Links. Online Inquiry; Featured Products; Events; Webinars; About Us; Time to Go GMP? kg to MT scale Cleanroom Class 100 to Class 100,000 HPAPI production with OEL . 1 μg/m³ Read More. Publication citing
【のレジャー】 メジャークラフト ライフジャケット ブルー BSJ …
WebBSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells. WebBSJ-01-175 Authors : Anand, K.; Dust, S.; Kaltheuner, I.H.; Geyer, M. Deposited on : 2024-03-18 This is a ullF wwPDB X-ray Structure alidationV Report for a publicly released PDB entry. We welcome your comments at [email protected] A user guide is aailablev at email security gateway appliance 300
BSJ-01-175 - epigenetics modulation frontier
WebBSJ-01-175. BSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells [1]. All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use. WebStructure-activity relationship study of THZ531 derivatives found that CDK12/13 dual inhibitor BSJ-01-175 could treat Ewing's sarcoma [43]. CDK12 promoted cervical cancer progression by enhancing ... WebApr 20, 2024 · Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Baishan Jiang Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry … email security application comparison